Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept

NCT03312855 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

334

Enrollment

OTHER

Sponsor class

Conditions

Stable Coronary Artery Disease

Interventions

DRUG: Revacept 80 mg
DRUG: Revacept 160 mg
DRUG: Placebo

Sponsor

Deutsches Herzzentrum Muenchen

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]